| abstract |
The present invention provides the following compounds of formula (I) or pharmaceutically acceptable salts thereof, and compositions containing them and their preparations, intermediates used in the synthesis of compounds of formula (I) and the use thereof. Compounds of formula (I) are NMDA receptor antagonists useful for the treatment of acute neurodegeneration and chronic neurological diseases.n n n <Formula I>n n n n n n n n Wheren n n R is a 5-membered ring heteroaryl group containing 3 or 4 nitrogen hetero atoms, linked to a quinoxalinedione ring by a ring carbon or nitrogen atom, or 1 to 3 linked to a quinoxalinedione ring by a ring carbon atom 6-membered ring heteroaryl groups containing two nitrogen heteroatoms, which heteroaryl groups are optionally benzo fused and include C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 3 -C 7 Cycloalkyl, halo, hydroxy, C 1 -C 4 alkoxy, C 3 -C 7 cycloalkyloxy, -COOH, C 1 -C 4 alkoxycarbonyl, -CONR 3 R 4 , -NR 3 R 4 , -S (O) p (C 1 -C 4 alkyl), -SO 2 NR 3 R 4 , by 1 or 2 substituents each independently selected from aryl, aryloxy, aryl (C 1 -C 4 ) alkoxy and het optionally substituted, wherein the C 1 -C 4 alkyl C 3 -C 7 cycloalkyl, halo, hydroxy, C 1 -C 4 alkoxy, halo (C 1 -C 4) alkoxy, C 3 -C 7 Claw alkyloxy, C 3 -C 7 cycloalkyl (C 1 -C 4) alkoxy, -COOH, C 1 -C 4 alkoxycarbonyl, -CONR 3 R 4, -NR 3 R 4, -S (O) p Optionally substituted by (C 1 -C 4 alkyl), -SO 2 (aryl), -SO 2 NR 3 R 4 , morpholino, aryl, aryloxy, aryl (C 1 -C 4 ) alkoxy or het, Said C 2 -C 4 alkenyl is optionally substituted by aryl;n n n R 1 and R 2 are each independently selected from H, fluoro, chloro, bromo, C 1 -C 4 alkyl and halo (C 1 -C 4 ) alkyl;n n n R 3 and R 4 are each independently selected from H and C 1 -C 4 alkyl or together form C 5 -C 7 alkylene;n n n p is 0, 1 or 2. |